uniQure N.V. Q2 2025 Earnings Recap

uniQure's second quarter of 2025 demonstrated significant advances in its clinical pipeline, highlighted by regulatory progress and manufacturing readiness for AMT-130, positioning the company for a potentially transformative second half of the year.

Key Takeaways

• Achieved breakthrough therapy designation for AMT-130 in Huntington's disease, marking a pivotal step in regulatory alignment.
• Completed manufacturing of two pre-PPQ GMP batches and advanced to the formal PPQ campaign, ensuring BLA readiness for early 2026 submission.
• Received alignment from the FDA on the statistical analysis plan, validating the use of an external control for the AMT-130 registrational endpoint.
• Early clinical data for AMT-260 shows a promising 92% reduction in seizure frequency for the first patient treated, generating interest in the epilepsy community.
• Continued preparation for a potential commercial launch in 2026, with key leadership appointments and strategic recruitment efforts underway.